Multiple sclerosis:Two new trials show,the cancer drug alemtuzumab (Campath) reduces the risk of disease relapse in people with multiple sclerosis.British researchers led by Alastair Compston of the University of Cambridge compared alemtuzumab with interferon beta 1a, the most common drug used to treat MS.In both trials, alemtuzumab appeared to increase the risk of certain autoimmune disorders, particularly those affecting the thyroid.Disability rates were 13 percent among those in the alemtuzumab group and 20 percent of those in the interferon beta 1a group. The first trial found no significant difference in disability rates between the two groups of patients.
...MS occurs when the body's immune system starts to attack the coating of nerve fibers.
Alemtuzumab, which is used to treat leukemia and other cancers of the immune system, works by altering the number, proportions and functions of certain types of lymphocytes, which are white blood cells that play a major role in the functioning of the immune system.There is no cure for MS, and existing drugs only aim to reduce the symptoms of the disease.
tags:the cancer,MS,immune system
...MS occurs when the body's immune system starts to attack the coating of nerve fibers.
Alemtuzumab, which is used to treat leukemia and other cancers of the immune system, works by altering the number, proportions and functions of certain types of lymphocytes, which are white blood cells that play a major role in the functioning of the immune system.There is no cure for MS, and existing drugs only aim to reduce the symptoms of the disease.
tags:the cancer,MS,immune system
No comments:
Post a Comment